OncoCyte (OCX) News Today $2.66 +0.06 (+2.12%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period OncoCyte (NASDAQ:OCX) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Tuesday.May 15 at 8:19 AM | marketbeat.comOncoCyte (NASDAQ:OCX) Releases Quarterly Earnings ResultsOncoCyte (NASDAQ:OCX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.26) EPS for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.May 14 at 6:33 PM | marketbeat.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13 at 6:52 AM | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13 at 1:52 AM | msn.comOncoCyte Corporation (OCX) Q1 2025 Earnings Call TranscriptMay 13 at 12:01 AM | seekingalpha.comOncocyte Reports Q1 2025 Results and Business ProgressMay 12 at 4:05 PM | globenewswire.comOncoCyte Q1 2025 Earnings PreviewMay 11, 2025 | msn.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Broadwood Capital Inc.Broadwood Capital Inc. grew its stake in shares of OncoCyte Co. (NASDAQ:OCX - Free Report) by 26.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,244,405 shares of the company's stock after purchasing an additionalMay 8, 2025 | marketbeat.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Trading Down 3.1% - Here's What HappenedOncoCyte (NASDAQ:OCX) Trading Down 3.1% - Here's WhyMay 2, 2025 | marketbeat.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $4.25 price objective on shares of OncoCyte in a research note on Tuesday.April 10, 2025 | marketbeat.comStockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)StockNews.com started coverage on OncoCyte in a report on Sunday. They issued a "sell" rating for the company.April 8, 2025 | marketbeat.comOncoCyte Co. (NASDAQ:OCX) Sees Large Growth in Short InterestOncoCyte Co. (NASDAQ:OCX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 373,800 shares, an increase of 22.4% from the February 28th total of 305,500 shares. Approximately 2.5% of the company's stock are sold short. Based on an average daily volume of 89,700 shares, the short-interest ratio is currently 4.2 days.April 4, 2025 | marketbeat.comOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comOncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on shares of OncoCyte in a research note on Monday. They set a "sell" rating on the stock.April 1, 2025 | marketbeat.comOncoCyte files to sell 10.61M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comOncoCyte Co. (NASDAQ:OCX) Shares Acquired by Pura Vida Investments LLCPura Vida Investments LLC boosted its stake in OncoCyte Co. (NASDAQ:OCX - Free Report) by 32.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 654,451 shares of the company's stock afterMarch 31, 2025 | marketbeat.comOncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at Lake Street CapitalLake Street Capital began coverage on shares of OncoCyte in a research note on Friday. They issued a "buy" rating and a $5.00 price objective for the company.March 29, 2025 | marketbeat.comOncoCyte initiated with a Buy at Lake StreetMarch 29, 2025 | markets.businessinsider.comLake Street Initiates Coverage of OncoCyte (OCX) with Buy RecommendationMarch 29, 2025 | msn.comEarnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advancesMarch 26, 2025 | uk.investing.comOncoCyte's (OCX) Equal Weight Rating Reiterated at StephensStephens restated an "equal weight" rating and issued a $4.00 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncoCyte's (OCX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $4.25 target price on shares of OncoCyte in a research note on Tuesday.March 26, 2025 | marketbeat.comOncocyte Corp. Reports Q4 2024 Results with $1.5 Million in Revenue and Significant Clinical Advancements in Transplant TestingMarch 26, 2025 | nasdaq.comOncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | msn.comOncoCyte (NASDAQ:OCX) Announces Earnings ResultsOncoCyte (NASDAQ:OCX - Get Free Report) announced its earnings results on Monday. The company reported $0.48 earnings per share for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%.March 25, 2025 | marketbeat.comOncocyte targets $20M in recurring revenue from 20 transplant centers by 2025March 24, 2025 | msn.comOncoCyte Corporation (OCX) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | seekingalpha.comOncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsMarch 24, 2025 | globenewswire.comOncoCyte Corporation (OCX): Among Top Insider Purchases Last MonthMarch 14, 2025 | msn.comOncoCyte (NASDAQ:OCX) Trading Up 14.7% - Should You Buy?OncoCyte (NASDAQ:OCX) Trading Up 14.7% - Here's WhyMarch 5, 2025 | marketbeat.comOncoCyte Corporation (OCX): Among Penny Stocks with Insider Buying in 2025March 4, 2025 | msn.comOncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.comOncocyte corp CFO buys $200,000 in stockFebruary 12, 2025 | msn.comAndrea S. James Buys 97,561 Shares of OncoCyte Co. (NASDAQ:OCX) StockFebruary 12, 2025 | insidertrades.comOncocyte corp's Patrick Smith acquires shares worth $2.2 millionFebruary 11, 2025 | msn.comBroadwood Partners acquires OncoCyte shares worth $9.24 millionFebruary 11, 2025 | msn.comOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 11, 2025 | globenewswire.comOncocyte Prices $29.1 Million Equity OfferingFebruary 10, 2025 | globenewswire.comOncocyte corp investor Patrick Smith buys $1,839 in sharesFebruary 5, 2025 | msn.comInsider Stock Buying Reaches US$508.4k On OncoCyteJanuary 31, 2025 | finance.yahoo.comOncoCyte stock hits 52-week low at $1.92 amid market challengesJanuary 22, 2025 | msn.comInsider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases 5,669 Shares of StockJanuary 16, 2025 | insidertrades.comOncoCyte appoints Billings as consulting CMOJanuary 8, 2025 | markets.businessinsider.comOncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerJanuary 8, 2025 | globenewswire.comOncocyte Expands Market Opportunity for VitaGraft™ KidneyJanuary 6, 2025 | globenewswire.com Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Media Mentions By Week OCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCX News Sentiment▼0.110.80▲Average Medical News Sentiment OCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCX Articles This Week▼102▲OCX Articles Average Week Get OncoCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcturus Therapeutics News Heron Therapeutics News Septerna News Benitec Biopharma News Fulcrum Therapeutics News Atyr PHARMA News Atai Life Sciences News Aurora Cannabis News Aquestive Therapeutics News Compass Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCX) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
